Brokerages Anticipate Harrow Health (NASDAQ:HROW) to Post ($0.06) Earnings Per Share
Harrow Health (NASDAQ:HROW) has received an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a one year consensus target price of $11.38 for the company and are predicting that the company will post ($0.06) EPS for the current quarter, according to Zacks. Zacks has also given Harrow Health an industry rank of 78 out of 256 based on the ratings given to its competitors.
HROW has been the topic of a number of recent analyst reports. ValuEngine raised shares of YPF from a “sell” rating to a “hold” rating in a research report on Monday, June 24th. Zacks Investment Research lowered shares of HEXO from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. Finally, TheStreet lowered shares of ZTO Express (Cayman) from a “b+” rating to a “c” rating in a research report on Wednesday, May 1st.
Harrow Health (NASDAQ:HROW) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.02) EPS for the quarter, missing the Zacks’ consensus estimate of $0.12 by ($0.14). Harrow Health had a net margin of 65.84% and a return on equity of 100.84%. The firm had revenue of $12.29 million during the quarter, compared to the consensus estimate of $12.10 million. On average, equities analysts expect that Harrow Health will post -0.1 earnings per share for the current fiscal year.
In related news, Director Robert J. Kammer sold 6,500 shares of the business’s stock in a transaction on Monday, July 15th. The shares were sold at an average price of $7.91, for a total transaction of $51,415.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert J. Kammer sold 10,000 shares of the business’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $4.57, for a total transaction of $45,700.00. The disclosure for this sale can be found here. Insiders have sold 26,500 shares of company stock worth $154,915 in the last ninety days. 12.43% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in HROW. Acadian Asset Management LLC bought a new stake in Harrow Health in the 1st quarter valued at $1,983,000. Granite Investment Partners LLC bought a new stake in Harrow Health in the 1st quarter valued at $1,254,000. Marshall Wace LLP bought a new stake in Harrow Health in the 1st quarter valued at $1,104,000. Birchview Capital LP bought a new stake in Harrow Health in the 1st quarter valued at $896,000. Finally, Corrado Advisors LLC bought a new stake in Harrow Health in the 2nd quarter valued at $475,000. 32.08% of the stock is currently owned by institutional investors and hedge funds.
About Harrow Health
Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.